Abstract:Abstract Introduction Obesity has been estimated to be prevalent in 70% of patients with obstructive sleep apnea (OSA). In SURMOUNT-1, phase 3, 72-week, randomized, double-blind clinical trial in participants with obesity or overweight, those treated with tirzepatide achieved significantly greater weight reduction than placebo. Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. The current post-hoc analysis assessed efficacy of tirzepatide versus placebo on weight reduction in participants with OSA and obesity or overweight. Methods MMRM analysis was conducted in SURMOUNT-1 participants reporting a baseline medical history of “apnoea”, “positive airway pressure therapy” or “sleep apnoea syndrome”. Weight loss measures were assessed in participants on treatment (efficacy estimand) using the modified intention-to-treat analysis set (participants who received at least one dose of study drug (tirzepatide 5mg, 10mg, 15mg, or placebo)). Results There were 197 participants with OSA included in this analysis (tirzepatide 5mg n=41, 10mg n=51, 15mg n=46, and placebo n=59), with baseline age of 48-53 years, body weight 110-122 kg, BMI 39-43kg/m2, presence of hypertension 48-73%, and proportion of females 42-53%. At week 72, estimated treatment difference between tirzepatide and placebo in mean percent weight change was -11.2% (5mg), -18.2% (10mg), and -20.7% (15mg), all P< 0.001. Significantly more participants treated with tirzepatide achieved ≥5% body weight reduction (83-98% treated with tirzepatide, 25% with placebo) and ≥10% body weight reduction (46-93% treated with tirzepatide, 15% with placebo) than those treated with placebo (all P< 0.001). 27-62% of participants treated with tirzepatide achieved ≥20% body weight reduction compared to 0% in the placebo group (tirzepatide 5mg P=0.006, 10mg and 15mg P< 0.001). All doses of tirzepatide significantly reduced waist circumference from baseline to week 72 (-10.6cm, -18.2cm, -18.9cm, all P< 0.001). Placebo did not significantly reduce waist circumference at week 72 compared to baseline (-3.5cm, P=0.053). Conclusion Participants with OSA and obesity or overweight treated with tirzepatide had significantly greater weight reduction than those treated with placebo in the SURMOUNT-1 trial. This degree of weight loss would be expected to have a clinically meaningful impact on OSA severity and is being investigated in the SURMOUNT-OSA trial. Support (if any) Eli Lilly and Company.

Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by CPAP: Randomised phase 3 study

Comparative efficacy, safety and benefit/risk of alerting agents for excessive daytime sleepiness in patients with obstructive sleep apnoea: a network meta-analysis

0648 Phase 3 Randomized Placebo-Controlled Trial of Pitolisant for Excessive Daytime Sleepiness in Prader-Willi Syndrome

0631 Phase 2, Proof-of-Concept Study of Pitolisant in Prader-Willi Syndrome: Primary and Secondary Efficacy Analyses

Is pitolisant safe for clinical use? A retrospective pharmacovigilance study focus on the post‐marketing safety

Excessive daytime sleepiness in obstructive sleep apnea: Indirect treatment comparison of wake-promoting agents in patients adherent/nonadherent to primary OSA therapy

Determination of thresholds for minimally important difference and clinically important response on the functional outcomes of sleep questionnaire short version in adults with narcolepsy or obstructive sleep apnea

Evaluating pharmacological treatments for excessive daytime sleepiness in obstructive sleep apnea: A comprehensive network meta-analysis and systematic review

Late Breaking Abstract - A randomized, double-blind, placebo controlled, dose-finding trial of sulthiame in obstructive sleep apnea

Gefapixant as a P2X3 receptor antagonist treatment for obstructive sleep apnea: a randomized controlled trial

Effect of CPAP vs. mandibular advancement device for excessive daytime sleepiness, fatigue, mood, sustained attention, and quality of life in patients with mild OSA

Guidelines for the assessment and management of residual sleepiness in obstructive apnea-hypopnea syndrome: Endorsed by the French Sleep Research and Medicine Society (SFRMS) and the French Speaking Society of Respiratory Diseases (SPLF)

Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sample baseline characteristics of the SURMOUNT -OSA phase 3 trial

0546 Aroxybutynin and Atomoxetine for the Treatment of OSA: Rationale and Design of the SYNAIRGY Phase 3 RCT

Hypoglossal nerve stimulation versus positive airway pressure therapy for obstructive sleep apnea

0620 Effect of Tirzepatide on Weight Loss in Patients with Obstructive Sleep Apnea and Obesity from SURMOUNT-1

Antiparkinsonian drug-induced sleepiness: a double-blind placebo-controlled study of L-dopa, bromocriptine and pramipexole in healthy subjects

Effect of CPAP on circulating levels of MPO and MMP-9 in adults with coronary artery disease and obstructive sleep apnoea: the RICCADSA randomized controlled trial

0468 A Multiple Dose, Placebo-Controlled, Randomized Double-Blind, Multicenter Study to Investigate Triprolidine in the Treatment of Temporary Sleep Disturbance

0630 Efficacy of Sodium Oxybate in Adults with Idiopathic Hypersomnia : A Randomized Placebo-controlled Trial

0650 Safety and Efficacy of KP1077 in a Phase 2, Double-Blind, Randomized Trial in Patients with Idiopathic Hypersomnia